What is Enliven Therapeutics's net investment in lease?

Enliven Therapeutics (ELVN) reported net investment in lease of $290K in Q1 2026.

How has Enliven Therapeutics's net investment in lease changed year-over-year?

Enliven Therapeutics's net investment in lease decreased by 58.6% year-over-year, from $700K to $290K.

What is the long-term trend for Enliven Therapeutics's net investment in lease?

Over 4 years (2021 to 2025), Enliven Therapeutics's net investment in lease has grown at a -7.6% compound annual growth rate (CAGR), from $525K to $383K.

Enliven Therapeutics ELVN Net Investment in Lease

Net Investment in Lease at other companies

Iovance Biotherapeutics, Inc.IOVA

——

ImmunomeIMNM

——

Nuvation BioNUVB

——

ImmunityBio, Inc.IBRX

——

Syndax PharmaceuticalsSNDX

——

ArriVent BioPharma, Inc.AVBP

——

Other financials

Income statement

See full

Operating income-$27.8M+12.2%

Net income-$23.6M+17.2%

EPS (diluted)-$0.38+33.3%

Balance sheet

See full

Cash & equivalents$132.2M+30.0%

Total debt$302.0K-56.9%

Total equity$453.4M+57.3%

Total assets$464.9M+53.6%

Cash flow

See full

Operating cash flow-$19.3M+20.0%

CapEx--100%

Free cash flow-$19.3M+20.1%

Valuation

See full

Market cap$3.47B+143%

Enterprise value$3.34B+156%

Returns & leverage

See full

Return on equity-26.6%-3.5pp

Debt / equity0×0.0×

Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enliven Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Enliven Therapeutics's net investment in lease?: Enliven Therapeutics (ELVN) reported net investment in lease of $290K in Q1 2026.
How has Enliven Therapeutics's net investment in lease changed year-over-year?: Enliven Therapeutics's net investment in lease decreased by 58.6% year-over-year, from $700K to $290K.
What is the long-term trend for Enliven Therapeutics's net investment in lease?: Over 4 years (2021 to 2025), Enliven Therapeutics's net investment in lease has grown at a -7.6% compound annual growth rate (CAGR), from $525K to $383K.